ClinicalTrials.gg
Active, not recruitingNCT06697925THORSDOTTIRUpdated Nov 12, 2026

Evaluating the Durability of Closure for Venous Leg Ulcers

An observational study in Venous Leg, Venous Leg Ulcer (VLU) and Venous Leg Ulcer, sponsored by Kerecis Ltd.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Kerecis Ltd. (part of Coloplast A/S) · Observational

How we know

Updated Nov 12, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Varicose Ulcer with a site in United States — 33 open to participants now, 43 under way, 4 of them phase 3. Varicose Ulcer · United States.

Planned enrollment
15th of 23
150 · median 300
Started
2025
with 11 others
Observational
23 of 155
6 open now
Primary completion
2026-11
later than 16 of 42 live
Registered
136th of 155
by date
Lead sponsor
3 of 155
Kerecis Ltd.

Among the 155 studies in Varicose Ulcer with a site in United States, this one is the 15th largest by planned enrollment of the 23 observational ones that give a count, is one of 12 that started in 2025, is one of 23 observational ones, reaches primary completion later than 16 of the 42 other live ones, and was the 136th registered.

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

33 of the 155 studies in Varicose Ulcer with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Varicose Ulcer with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to determine the durability of closure for venous leg ulcer subjects that achieved closure in the THOR trial.

Read the detailed description

To determine durability of closure (rate of target wound recurrence) of subjects with a closed venous leg ulcer during the THOR clinical trial comparing subjects treated with Intact Fish Skin Graft (IFSG) plus standard of care (SOC) to subjects treated with SOC alone.

03

Conditions studied

  • Venous Leg
  • Venous Leg Ulcer (VLU)
  • Venous Leg Ulcer
  • Venous Ulcer
  • VLU

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who achieved closure in during the THOR clinical trial

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Subjects must have participated in the THOR trial and achieved complete closure by the 12-week endpoint.

Exclusion criteria

Exclusion Criteria:

  • 1. Subjects who did not participate in the THOR trial. 2. Subjects who participated in the THOR trial and did not achieve complete closure.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Thor closure patients

    Patients who achieved closure in during the THOR clinical trial

06

What researchers measure

Primary outcomes

  1. Durability of closure

    To demonstrate durability of closure (rate of target wound recurrence) of subjects with a closed venous leg ulcer during the THOR clinical trial comparing subjects treated with Intact Fish Skin Graft (IFSG) plus standard of care (SOC) to subjects treated with SOC alone.

    Time frame: 12-month follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 28 observational studies under Varicose Ulcer, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 141. This study's planned 18 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jan 2025 → May 2025, primary completion Oct 2026 → Nov 2026 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
May 23, 2025was Jan 2025
Primary completionEst.
Nov 2026was Oct 2026
CompletionEst.
Mar 2027was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Start date
Jan 2025→May 23, 2025 (actual)
Nov 12, 2026
Primary completion
Oct 2026→Nov 2026
Nov 12, 2026
Study completion
Dec 2026→Mar 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Start date Jan 2025→May 23, 2025 (now actual)
    Primary completion Oct 2026→Nov 2026
    Study completion Dec 2026→Mar 2027
    + 4 other changes: verification date, criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06697925
Lead sponsor
Kerecis Ltd.
Collaborators
Serena Group
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
May 23, 2025
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion